검색어 : 통합검색[Vaughn Margaret]
총 196건 중 196건 출력
, 20/20 페이지
-
191
- Metabolic syndrome (MetS) after platinum-based chemotherapy (CHEM): A multicenter study of North American testicular cancer survivors (TCS).
- Abu Zaid, Mohammad Issam; Gathirua-Mwangi, Wambui G.; Williams, AnnaLynn; Fung, Chunkit; Monahan, Patrick O.; Feldman, Darren R.; Hamilton, Robert James; Vaughn, David J.; Beard, Clair; Cook, Ryan; Althouse, Sandra K.; El Charif, Omar; Sesso, Howard D.; Ardeshirrouhanifard, Shirin; Einhorn, Lawrence H.; Fossa, Sophie D.; Travis, Lois B.; Indiana University School of Medicine, Indianapolis, IN; ; Indiana University School of Medicine, Indianapolis, IN; ; University of Rochester School of Medicine and Dentistry, Rochester, NY; ; Univ of Rochester Medcl Ctr, Rochester, NY; ; Indiana University School of Medicine, Indianapolis, IN; ; Memorial Sloan Kettering Cancer Center, New York, NY; ; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; ; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; ; Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA; ; Indiana University School of Medicine, Indianapolis, IN; ; Indiana University School of Medicine, Indianapolis, IN; ; The University of Chicago, Chicago, IL; ; Division of Preventive Medicine, Harvard Medical School, Boston, MA; ; Indiana University School of Medicine, Indianapolis, IN; ; Indiana University School of Medicine, Indianapolis, IN; ; The Norwegian Radium Hospital, Oslo, Norway; ; Indiana Univers; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.35, 2017, pp.102-102)
-
192
- Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).
- Abu Zaid, Mohammad Issam; Menendez, Alvaro G.; El Charif, Omar; Fung, Chunkit; Monahan, Patrick O.; Feldman, Darren R.; Hamilton, Robert James; Vaughn, David J.; Beard, Clair; Cook, Ryan; Althouse, Sandra K.; Sesso, Howard D.; Ardeshirrouhanifard, Shirin; Dinh, Paul C; Einhorn, Lawrence; Fosså , Sophie; Travis, Lois B.; Indiana University School of Medicine, Indianapolis, IN; ; Indiana University School of Medicine, Indianapolis, IN; ; The University of Chicago, Chicago, IL; ; University of Rochester Medical Center, Rochester, NY; ; Indiana University School of Medicine, Indianapolis, IN; ; Memorial Sloan-Kettering Cancer Center, New York, NY; ; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; ; Abramson Cancer Center, Philadelphia, PA; ; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; ; Indiana University School of Medicine, Indianapolis, IN; ; Indiana University School of Medicine, Indianapolis, IN; ; Division of Preventive Medicine, Harvard Medical School, Boston, MA; ; Indiana University School of Medicine, Indianapolis, IN; ; Indiana University School of Medicine, Indianapolis, IN; ; Indiana University School of Medicine, Indianapolis, IN; ; National Advisory Unit on Late Effects After Cancer Treatment, Oslo, Norway; ; Indiana University Scho; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.35, 2017, pp.LBA10012-LBA10012)
-
193
- Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms
- El Charif, Omar; Mapes, Brandon; Trendowski, Matthew R.; Wheeler, Heather E.; Wing, Claudia; Dinh Jr, Paul C.; Frisina, Robert D.; Feldman, Darren R.; Hamilton, Robert J.; Vaughn, David J.; Fung, Chunkit; Kollmannsberger, Christian; Mushiroda, Taisei; Kubo, Michiaki; Gamazon, Eric R.; Cox, Nancy J.; Huddart, Robert; Ardeshir-Rouhani-Fard, Shirin; Monahan, Patrick; Fossa, Sophie D.; Einhorn, Lawrence H.; Travis, Lois B.; Dolan, M. Eileen; Department of Medicine, University of Chicago, Chicago, Illinois.; Department of Medicine, University of Chicago, Chicago, Illinois.; Department of Medicine, University of Chicago, Chicago, Illinois.; Departments of Biology and Computer Science, Loyola University Chicago, Chicago, Illinois.; Department of Medicine, University of Chicago, Chicago, Illinois.; Department of Medical Oncology, Indiana University, Indianapolis, Indiana.; Departments of Medical and Chemical & Biomolecular Engineering and Communication Sciences & Disorders, Global Center for Hearing and Speech Research, University of South Florida, Tampa, Florida.; Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.; Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.; J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.; (Clinical Cancer research : an official journal of the American Association for Cancer Research, v.25, 2019, pp.4104-4116)
-
194
- Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database
- Lauritsen, Jakob; Sauvé , Nicolas; Tryakin, Alexey; Jiang, Di Maria; Huddart, Robert; Heng, Daniel Y. C.; Terbuch, Angelika; Winquist, Eric; Chovanec, Michal; Hentrich, Marcus; Fankhauser, Christian D.; Shamash, Jonathan; del Muro, Xavier Garcia; Vaughn, David; Heidenreich, Axel; Sternberg, Cora N.; Sweeney, Christopher; Necchi, Andrea; Bokemeyer, Carsten; Bandak, Mikkel; Jandari, Abolghassem; Collette, Laurence; Gillessen, Silke; Beyer, Joerg; Daugaard, Gedske; Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Department of Chemotherapy, N.N.Blokhin Russian Cancer Research Center, Moscow, Russia; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON Canada; Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey UK; Division of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta Canada; Division of Oncology, Medical University of Graz, Graz, Austria; Department of Oncology, University of Western Ontario and London Health Sciences Centre, London, ON Canada; 2nd Department of Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovakia; Department of Hematology/Oncology, Red Cross Hospital, Munich, Germany; University of Zurich, Zurich, Switzerland; Department of; (The British journal of cancer, v.129, 2023, pp.1759-1765)
-
195
- Clinical, sociodemographic, and behavioral factors associated with cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study.
- Kerns, Sarah L.; Fung, Chunkit; Williams, AnnaLynn; Abu Zaid, Mohammad Issam; Sesso, Howard D.; Monahan, Patrick; Ardeshirrouhanifard, Shirin; Feldman, Darren R.; Hamilton, Robert James; Vaughn, David J.; Beard, Clair; Huddart, Robert Anthony; Kim, Jeri; Kollmannsberger, Christian K.; Sahasrabudhe, Deepak M.; Morlang, Ashley Amidon; Cook, Ryan; Fossa, Sophie D.; Einhorn, Lawrence H.; Travis, Lois B.; University of Rochester Medical Center, Rochester, NY; ; University of Rochester Medical Center, Rochester, NY; ; University of Rochester Medical Center, Rochester, NY; ; Indiana University School of Medicine, Indianapolis, IN; ; Division of Preventive Medicine, Harvard Medical School, Boston, MA; ; Indiana University, Indianapolis, IN; ; Indiana University School of Medicine, Indianapolis, IN; ; Memorial Sloan-Kettering Cancer Center, New York, NY; ; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; ; Abramson Cancer Center, Philadelphia, PA; ; Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; ; Institute of Cancer Research, Sutton, United Kingdom; ; The University of Texas MD Anderson Cancer Center, Houston, TX; ; BC Cancer Agency - Vancouver Centre, Vancouver, BC, Canada; ; Wilmot Cancer Center, Rochester, NY; ; University of Rochester Medical Center, Rochester, NY; ; Indiana University School of Medicine, Indianapolis, IN; ; Oslo; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.35, 2017, pp.10075-10075)
-
196
- Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.
- Pond, Gregory Russell; Sonpavde, Guru; Choueiri, Toni K.; Qu, Angela Q.; Vaughn, David J.; Fougeray, Ronan; Niegisch, Guenter; Albers, Peter; Wong, Yu-Ning; Ko, Yoo-Joung; Sridhar, Srikala S.; Galsky, Matt D.; Petrylak, Daniel Peter; Beer, Tomasz M.; Stadler, Walter Michael; O'Donnell, Peter H.; Sternberg, Cora N.; Rosenberg, Jonathan E.; Molins, Joaquim Bellmunt; McMaster University, Hamilton, ON, Canada; Texas Oncology, Houston, TX, and Department of Medicine, Section of Medical Oncology, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Institut de Recherche Pierre Fabre, Boulogne, France; Department of Urology, Heinrich-Heine-University, Duesseldorf, Germany; Heinrich Heine University, Duesseldorf, Germany; Fox Chase Cancer Center, Philadelphia, PA; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; University Health Network, Princess Margaret Hospital, Toronto, ON, Canada; Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY; Columbia University College of; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.30, 2012, pp.4522-4522)
QUICK MENU
